In a filing, ARS Pharmaceuticals Inc revealed its Director Shawver Laura unloaded Company’s shares for reported $0.56 million on Mar 06 ’25. In the deal valued at $11.21 per share,49,600 shares were sold. As a result of this transaction, Shawver Laura now holds 210,346 shares worth roughly $2.28 million.
Then, Shawver Laura sold 400 shares, generating $4,400 in total proceeds. Upon selling the shares at $11.00, the Director now owns 210,346 shares.
Before that, Shawver Laura bought 50,000 shares. ARS Pharmaceuticals Inc shares valued at $550,000 were divested by the Director at a price of $11.00 per share.
Scotiabank initiated its ARS Pharmaceuticals Inc [SPRY] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $30. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering SPRY with “an Overweight” recommendation on August 20, 2024. Raymond James revised its rating on August 13, 2024. It rated SPRY as “a Strong buy” which previously was an “an Outperform”.
Price Performance Review of SPRY
On Monday, ARS Pharmaceuticals Inc [NASDAQ:SPRY] saw its stock fall -0.18% to $10.83. Over the last five days, the stock has gained 6.39%. ARS Pharmaceuticals Inc shares have risen nearly 2.65% since the year began. Nevertheless, the stocks have risen 21.41% over the past one year. While a 52-week high of $18.51 was reached on 01/27/25, a 52-week low of $7.55 was recorded on 03/04/25. SMA at 50 days reached $11.82, while 200 days put it at $12.14.
Levels Of Support And Resistance For SPRY Stock
The 24-hour chart illustrates a support level at 10.54, which if violated will result in even more drops to 10.26. On the upside, there is a resistance level at 11.03. A further resistance level may holdings at 11.24. The Relative Strength Index (RSI) on the 14-day chart is 42.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.07%. Stochastics %K at 35.14% indicates the stock is a holding.
The most recent change occurred on August 12, 2024 when Leerink Partners resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $20.
